Jasper Therapeutics presents updated clinical data on briquilimab for CSU treatment
From GlobeNewswire: 2025-03-01 12:45:13
Jasper Therapeutics presented updated clinical data on briquilimab at the AAAAI 2025 Annual Meeting. The Phase 1b/2a BEACON study showed favorable safety and tolerability with no new adverse events. The data support advancing briquilimab into a registrational program for chronic spontaneous urticaria (CSU). The company plans to start a Phase 2b study in the second half of 2025. Additional data on doses of 180mg and higher will be reported mid-year. The therapy demonstrated rapid and deep clinical responses in patients with moderate to severe CSU, offering a potential differentiated treatment option.
Jasper remains enthusiastic about the efficacy and safety data from the BEACON study, showcasing the potential of briquilimab compared to other therapies. With more patients enrolled in ongoing studies, the company expects to report data from approximately 70 additional patients by mid-year 2025. The data will inform the final dose selection for the planned Phase 2b study later in the year. Briquilimab, a targeted monoclonal antibody, aims to deplete mast cells through apoptosis, addressing inflammatory responses in mast cell-driven diseases like chronic urticaria and asthma. The therapy has shown positive outcomes in clinical trials and has a promising future for patients with CSU, CIndU, or asthma.
Read more at GlobeNewswire: Jasper Therapeutics Presents Clinical and Preclinical